Pharmacogenomic analysis in patients with familial hypercholesterolemia (2022)
- Authors:
- Autor USP: HERNANDEZ, CAROLINA DAGLI - FCF
- Unidade: FCF
- Sigla do Departamento: FBC
- DOI: 10.11606/T.9.2022.tde-20052022-121840
- Subjects: FARMACOGENÉTICA; HIPERCOLESTEROLEMIA; ESTATINAS
- Keywords: Adverse drugs events; Estatina; Eventos adversos a medicamentos; Familial hypercholesterolemia; Farmacogenética; Hipercolesterolemia familial; Mialgia; Myalgia; Pharmacogenetics; Statin
- Agências de fomento:
- Language: Inglês
- Abstract: Introduction: Familial hypercholesterolemia (FH) is a monogenic dyslipidemia with a high risk of developing early atherosclerotic disease. Statins are the first-line treatment of FH patients. Statins substantially reduce low-density lipoprotein cholesterol (LDL-c) and have a good efficacy and safety profile. However, some patients do not respond adequately whereas others experience statin-related adverse events (SRAE). Genetic and non-genetic factors contribute to the variability in the response to statins, but there are few studies on pharmacogenomic factors in the Brazilian population. Objective: To explore the association of genetic variants with the response to lipid-lowering drugs and SRAE in Brazilian FH patients Patients and Methods: Adult FH patients (n=114) were selected and clinical and pharmacotherapeutic data were obtained. The response to statin treatment was considered as LDL-c reduction of at least 50%. Blood samples were obtained for laboratory testing and genomic DNA extraction. A panel of 84 genes (related to HF and pharmacogenes) was analyzed by exon-targeted gene sequencing (ETGS). The DNA sequencing data was analyzed using a variant discovery pipeline. The functional impact of variants in pharmacokinetics (PK)- and pharmacodynamics (PD)-related genes was assessed using a functionality prediction score (FPS) and other in silico tools. LDL-c response to statin and SRAE risk was in carriers of deleterious variants in PK and PD genes, with minor allele frequency (MAF) > 5.0% or 10%, using univariate and multivariate linear regression analyses. Molecular modeling analysis was used to explore the functional effect in silico of deleterious variants. Results: Fifty-eight (50.8%) of the FH patients responded to statins and 24 (21.0) had SRAE. Obesity and alcohol consumption were more frequent in the non-responder (NRE) group (p<0.05), whereas the concomitant use of ezetimibe and SRAEwere more prevalent in the responder (RE) group (p<0.05). The ETGS revealed 21 pathogenic variants in FH-related genes (19 LDLR, 1 APOB and 1 PCSK9), 402 variants in 23 PK-related genes (186 missense, 2 stop-gain, 1 stop-loss, 10 frameshift indel, 5 inframe deletions, 16 in splicing region, 29 in the 5´UTR region, and 153 in the 3´UTR region), and 752 variants in 33 PD-related genes (249 missense, 1 stop-gain, 9 start-loss, 5 frameshift indel, 9 inframe indel, 26 in splice-sites, 67 in the 5´UTR region, and 386 in the 3´UTR region). Functional prediction analysis revealed 21 missense, 1 stop-loss, 7 splice and 10 frameshift/inframe variants in PK genes are deleterious. Multivariate regression analysis of 16 variants in ABC and SLC transporters and CYP metabolizing enzymes with MAF > 10.0% and adjustment for non-genetic covariates, revealed that ABCC1 rs45511401 (c.2012G>T, p.Gly671Val) and SLCO1B3 rs60140950 (c.683G>C) increased LDL-c reduction to statin treatment (p<0.05). Molecular modeling analysis revealed that Val671 enhance the interaction of ABCC1 with statins compared with reference protein (Gly671). In PD-related genes, 93 missense, 1 start-loss, 3 stop-gain, 10 splice-site and 4 frameshift variants were predicted to be deleterious. The missense variant LPA rs76062330 (c.5468G>T) was associated with higher LDL-c reduction, even after corrections (Adjusted p=0.001). Multivariate linear regression analysis showed that the variant KIF6 rs20455 (c.2155T>C) reduced the LDL-c response to atorvastatin (p=0.014), whereas multivariate logistic regression revealed association of LPA rs3124784 (c.6046C>T) with increased response to statins (p=0.022). Deleterious variants in PK- and PD- related genes were not associated with increased risk of SRAE in FH patients. Conclusions: The deleterious variants ABCC1 c.2012G>T, SLCO1B3 c.683G>C, LPA c.5468G>T and LPA c.6046C>Tenhanced LDL-c reduction in FH patients. KIF6 rs20455 (c.2155T>C), a neutral variant, decreased LDL-c reduction to atorvastatin. Deleterious variants in PK and PD genes were not associated with increased risk of SRAE
- Imprenta:
- Data da defesa: 09.02.2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-sa
-
ABNT
HERNANDEZ, Carolina Dagli. Pharmacogenomic analysis in patients with familial hypercholesterolemia. 2022. Tese (Doutorado) – Universidade de São Paulo, São Paulo, 2022. Disponível em: https://www.teses.usp.br/teses/disponiveis/9/9142/tde-20052022-121840/. Acesso em: 23 maio 2024. -
APA
Hernandez, C. D. (2022). Pharmacogenomic analysis in patients with familial hypercholesterolemia (Tese (Doutorado). Universidade de São Paulo, São Paulo. Recuperado de https://www.teses.usp.br/teses/disponiveis/9/9142/tde-20052022-121840/ -
NLM
Hernandez CD. Pharmacogenomic analysis in patients with familial hypercholesterolemia [Internet]. 2022 ;[citado 2024 maio 23 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9142/tde-20052022-121840/ -
Vancouver
Hernandez CD. Pharmacogenomic analysis in patients with familial hypercholesterolemia [Internet]. 2022 ;[citado 2024 maio 23 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9142/tde-20052022-121840/ - Unraveling the risk factors and etiology of the canine oral mucosal melanoma: results of an epidemiological questionnaire, oral microbiome analysis and investigation of papillomavirus infection
- Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts
- Proposta de medicina personalizada utilizando perfil farmacogenético em pacientes idosos usuários de varfarina
- Cardiovascular pharmacogenomics: an update on clinical studies of antithrombotic drugs in Brazilian patients
- In silico analysis of upstream variants in Brazilian patients with Familial hypercholesterolemia
- Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia
- Functional analysis of PCSK9 3'UTR variants and mRNA-miRNA interactions in patients with familial hypercholesterolemia
- Effects of PCSK9 missense variants on molecular conformation and biological activity in transfected HEK293FT cells
- Functional analysis of PCSK9 3′UTR variants and mRNA–miRNA interactions in patients with familial hypercholesterolemia
- Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with familial hypercholesterolemia: a case report
Informações sobre o DOI: 10.11606/T.9.2022.tde-20052022-121840 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas